Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04033627
Other study ID # TCD Haplo
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 10, 2020
Est. completion date May 8, 2024

Study information

Verified date September 2022
Source Shanghai Children's Medical Center
Contact luo chengjuan
Phone +86 021 38626161
Email luochengjuan@scmc.com.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-center clinical study in China using CliniMACS TCRα/β+ and CD45RA+ T cell depleted stem cell grafts from haploidentical donors for hematopoietic stem cell transplantation in children.


Description:

This clinical study will the CliniMACS TCRα/β and CD45RA Systems to deplete TCRα/β+ and CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donors to treat pediatric patients who were suffuring form relapsed or refactory leukemia. Aming to evaluate the safety/tolerability and feasibility of haploidentical PBSC grafts depleted of TCRα/β+ and CD45RA+ cells using the CliniMACS TCRαβ/CD45RA System in pediatric patients with hematological malignancies diseases. And the incidence of grade II-IV acute graft-versus-host disease (GVHD) until Day 100 post-transplantation of this new In Vitro T cell depletion technology in China. The investigators will monitor the incidence of grade I acute GVHD until Day 100 post-transplantation, incidence and severity of chronic GVHD after 1 year and 2 years, incidence of NRM at all visits throughout the study, and graft failure from Day 0 to Day 28 at the same time.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date May 8, 2024
Est. primary completion date July 18, 2022
Accepts healthy volunteers No
Gender All
Age group 2 Months to 18 Years
Eligibility Inclusion Criteria: Pediatric patients with hematological malignancies in complete remission (CR), partial remission (PR) or with stable disease - Acute myeloid leukemia (AML): Patients with high-risk AML in CR1 Patients with relapsed or primary therapy-refractory AML - Acute lymphoid leukemia (ALL): Patients with high-risk ALL in CR1 Patients with relapsed or primary refractory ALL Exclusion Criteria: - Age >18 years or <8 weeks - Patients with progressive disease prior HCT - <3 months after preceding hematopoietic cell transplantation (HCT) - History of neurological impairment (active seizures, severe peripheral neuropathy, signs of leukencephalopathy, active CNS infection) - Fungal infections with radiological and clinical progression - Liver function abnormalities with bilirubin >2 mg/dL and elevation of transaminases higher than 400 U/L - Chronic active viral hepatitis - Ejection fraction <40% or shortening fraction <25% on echocardiography - Patients with > grade II hypertension by Common Toxicity Criteria (CTC) - Creatinine clearance below threshold defined for stem cell transplantation according to local clinical standard - Respiratory failure necessitating supplemental oxygen - HIV infection - Concurrent severe or uncontrolled medical disease (e.g. uncontrolled diabetes, congestive heart failure, myocardial infarction within 6 months prior to the study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which by assessment of the treating physician could compromise participation in the study - Patients with a history of psychiatric illness or a condition which could interfere with their ability to understand the requirements of the study (this includes alcoholism/drug addiction) - Patients unwilling or unable to comply with the protocol or unable to give informed consent - Treatment with any investigational product within 4 weeks prior to study treatment (transfusion of the IMP)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
In Vitro T cells depletion using CliniMCAS system
Use the CliniMACS TCRa/ß and CD45 Systems to deplete TCRa/ß+ and CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donor in patients with leukemia.

Locations

Country Name City State
China Shanghai Children's Medical Center Shanghai

Sponsors (5)

Lead Sponsor Collaborator
Shanghai Children's Medical Center Children's Hospital Of Soochow University, Chinese University of Hong Kong, Miltenyi Biomedicine GmbH, Nanfang Hospital of Southern Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Log number of In Vitro T cells depletion Log number of In Vitro T cells depletion using CliniMACS TCRab/CD45RA system. One week
Primary Incidence of grade II-IV acute GVHD Incidence of grade II-IV acute graft-versus-host disease (GVHD) until Day 100 post-transplantation. up to 3 months
Secondary Grade I aGVHD Incidence of grade I acute GVHD until Day 100 post-transplantation up to 3 months
Secondary cGVHD Incidence and severity of chronic GVHD in 1 year and 2 years 2 years
Secondary NRM Incidence of NRM at all visits throughout the study 1 year
Secondary Graft failure incidence of Graft failure from Day 0 to Day 28 1 month
See also
  Status Clinical Trial Phase
Completed NCT04888468 - Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents Phase 1
Completed NCT04562792 - Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia Phase 2
Terminated NCT00439296 - ABT-751 With Chemotherapy for Relapsed Pediatric ALL Phase 1/Phase 2
Recruiting NCT03938987 - Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) Phase 1/Phase 2
Recruiting NCT05334823 - A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents Phase 2